Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer

[1]  A. Larsen,et al.  Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status , 2016, Targeted Oncology.

[2]  J. Soria,et al.  Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours , 2015, British Journal of Cancer.

[3]  Hai Hu,et al.  Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. , 2014, Oncology reports.

[4]  Yu-zhu Wang,et al.  ROCK Is Involved in Vasculogenic Mimicry Formation in Hepatocellular Carcinoma Cell Line , 2014, PloS one.

[5]  S. Misra,et al.  COX-2 signaling and cancer: new players in old arena. , 2014, Current drug targets.

[6]  N. K. Sah,et al.  Biology of Cox-2: an application in cancer therapeutics. , 2011, Current drug targets.

[7]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[8]  Lin Li,et al.  The role of Sp1 and Sp3 in normal and cancer cell biology. , 2010, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[9]  A. Lipton,et al.  Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer , 2010, Journal of clinical gastroenterology.

[10]  S. Mandal,et al.  COX-2 as a target for cancer chemotherapy , 2010, Pharmacological reports : PR.

[11]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[12]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[13]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[15]  Kaiming Xu,et al.  EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. , 2007, Cancer research.

[16]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[18]  P. Philip,et al.  A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer , 2005, Investigational New Drugs.

[19]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[20]  M. Goggins,et al.  Prevention and management of duodenal polyps in familial adenomatous polyposis , 2005, Gut.

[21]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[22]  J. Abbruzzese,et al.  Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity , 2004, Cancer Research.

[23]  Hong Qing,et al.  Transcriptional Regulation of BACE1, the β-Amyloid Precursor Protein β-Secretase, by Sp1 , 2004, Molecular and Cellular Biology.

[24]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[25]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[26]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[27]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[28]  T. Murphy,et al.  Evidence that Galpha(q)-coupled receptor-induced interleukin-6 mRNA in vascular smooth muscle cells involves the nuclear factor of activated T cells. , 2000, Molecular pharmacology.

[29]  M. Tachibana,et al.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[31]  N. Altorki,et al.  Inhibition of Cyclooxygenase-2 Gene Expression by p53* , 1999, The Journal of Biological Chemistry.

[32]  P. Isakson,et al.  The discovery and function of COX-2. , 1997, The Journal of rheumatology. Supplement.

[33]  C. J. McCarthy,et al.  Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. , 1997, Arthritis and rheumatism.

[34]  Robert Tjian,et al.  Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain , 1987, Cell.

[35]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[36]  J. Armitage,et al.  Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. , 2016, JAMA oncology.

[37]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[38]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[39]  J.,et al.  The New England Journal of Medicine , 2012 .

[40]  G. Collins.  The next generation. , 2006, Scientific American.

[41]  Hong Qing,et al.  Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. , 2004, Molecular and cellular biology.

[42]  T. Utsunomiya.  Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma , 2000 .

[43]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.